Trial Profile

A Phase 1/2 Exploratory Study of the TBL1 Inhibitor, Tegavivint (BC2059), in Patients With Advanced Hepatocellular Carcinoma

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 29 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tegavivint (Primary) ; Pembrolizumab
Indications Carcinoma; Liver cancer
Focus Adverse reactions
Sponsors Iterion Therapeutics

Most Recent Events

29 May 2024 Trial design presented in 60th Annual Meeting of the American Society of Clinical Oncology
20 Feb 2024 According to Iterion Therapeutics media release, company announced today first has been dosed and actively enrolling patients with advanced hepatocellular carcinoma in Phase 1b/2a clinical trial.
13 Sep 2023 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com